Literature DB >> 24440976

Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.

Melissa Kang1, Xiang J Shen1, Sangmi Kim2, Felix Araujo-Perez1, Joseph A Galanko1, Chris F Martin1, Robert S Sandler1, Temitope O Keku1.   

Abstract

BACKGROUND AND
OBJECTIVE: African Americans have worse outcomes in colorectal cancer (CRC) than Caucasians. We sought to determine if KRAS, BRAF and PIK3CA mutations might contribute to the racial differences in CRC outcome.
METHODS: DNA was extracted from tissue microarrays made from CRC samples from 67 African Americans and 237 Caucasians. Mutations in KRAS, BRAF, and PIK3CA were evaluated by PCR sequencing. We also examined microsatellite instability (MSI) status. Associations of mutation status with tumor stage and grade were examined using a logistic regression model. Cox proportional hazards models were used to estimate the all-cause mortality associated with mutational status, race and other clinicopathologic features.
RESULTS: KRAS mutations were more common in African Americans than among Caucasians (37% vs 21%, p=0.01) and were associated with advanced stage (unadjusted odds ratio (OR)=3.31, 95% confidence interval (CI) 1.03-10.61) and grade (unadjusted OR=5.60, 95% CI 1.01-31.95) among African Americans. Presence of BRAF mutations was also positively associated with advanced tumor stage (adjusted OR=3.99, 95%CI 1.43-11.12) and grade (adjusted OR=3.93, 95%CI 1.05-14.69). PIK3CA mutations showed a trend toward an association with an increased risk of death compared to absence of those mutations (adjusted for age, sex and CRC site HR=1.89, 95% CI 0.98-3.65). Among African Americans, the association was more evident (adjusted for age, sex and CRC site HR=3.92, 95% CI 1.03-14.93) and remained significant after adjustment for MSI-H status and combined education-income level, with HR of 12.22 (95%CI 1.32-121.38).
CONCLUSIONS: Our results suggest that African Americans may have different frequencies of somatic genetic alterations that may partially explain the worse prognosis among African Americans with CRC compared to whites.

Entities:  

Keywords:  African-Americans; BRAF; KRAS; PIK3CA; colorectal cancer

Mesh:

Substances:

Year:  2013        PMID: 24440976      PMCID: PMC4589188          DOI: 10.3233/CBM-130366

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  41 in total

1.  Impact of race/ethnicity on prognosis in patients who underwent surgery for colon cancer: analysis for white, African, and East Asian Americans.

Authors:  Yojiro Hashiguchi; Kazuo Hase; Hideki Ueno; Eiji Shinto; Yoshihisa Naito; Yoshiki Kajiwara; Toshihiko Kuroda; Junji Yamamoto; Hidetaka Mochizuki
Journal:  Ann Surg Oncol       Date:  2011-10-20       Impact factor: 5.344

2.  Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.

Authors:  Mai Yamauchi; Teppei Morikawa; Aya Kuchiba; Yu Imamura; Zhi Rong Qian; Reiko Nishihara; Xiaoyun Liao; Levi Waldron; Yujin Hoshida; Curtis Huttenhower; Andrew T Chan; Edward Giovannucci; Charles Fuchs; Shuji Ogino
Journal:  Gut       Date:  2012-03-17       Impact factor: 23.059

3.  Racial disparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics?

Authors:  Arica White; Sally W Vernon; Luisa Franzini; Xianglin L Du
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

4.  Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression.

Authors:  W Dietmaier; S Wallinger; T Bocker; F Kullmann; R Fishel; J Rüschoff
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

5.  BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

Authors:  Matthew F Kalady; Kathryn L Dejulius; Julian A Sanchez; Awad Jarrar; Xiuli Liu; Elena Manilich; Marek Skacel; James M Church
Journal:  Dis Colon Rectum       Date:  2012-02       Impact factor: 4.585

6.  Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

Authors:  Greg Yothers; Daniel J Sargent; Norman Wolmark; Richard M Goldberg; Michael J O'Connell; Jacqueline K Benedetti; Leonard B Saltz; James J Dignam; A William Blackstock
Journal:  J Natl Cancer Inst       Date:  2011-10-12       Impact factor: 13.506

Review 7.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

8.  PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.

Authors:  Shunsuke Kato; Satoru Iida; Tetsuro Higuchi; Toshiaki Ishikawa; Yoko Takagi; Masamichi Yasuno; Masayuki Enomoto; Hiroyuki Uetake; Kenichi Sugihara
Journal:  Int J Cancer       Date:  2007-10-15       Impact factor: 7.396

9.  Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans.

Authors:  Krishan Kumar; Hassan Brim; Francis Giardiello; Duane T Smoot; Mehdi Nouraie; Edward L Lee; Hassan Ashktorab
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

10.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

View more
  21 in total

Review 1.  Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.

Authors:  Z B Mei; C Y Duan; C B Li; L Cui; S Ogino
Journal:  Ann Oncol       Date:  2016-07-19       Impact factor: 32.976

2.  PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.

Authors:  Amanda I Phipps; Dennis J Ahnen; Iona Cheng; Polly A Newcomb; Aung Ko Win; Terrilea Burnett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-20       Impact factor: 4.254

Review 3.  Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms.

Authors:  Gaius J Augustus; Nathan A Ellis
Journal:  Am J Pathol       Date:  2017-11-09       Impact factor: 4.307

4.  Racial differences in colorectal cancer survival at a safety net hospital.

Authors:  Umit Tapan; Shin Yin Lee; Janice Weinberg; Vijaya B Kolachalama; Jean Francis; Marjory Charlot; Kevan Hartshorn; Vipul Chitalia
Journal:  Cancer Epidemiol       Date:  2017-05-21       Impact factor: 2.984

5.  Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.

Authors:  Zachary Hurst; Sandya Liyanarachchi; Huiling He; Pamela Brock; Jennifer Sipos; Fadi Nabhan; Electron Kebebew; Patience Green; Gilbert J Cote; Steven Sherman; Christopher J Walker; Yi Seok Chang; Shuai Xue; Brynn Hollingsworth; Wei Li; Luke Genutis; Eric Menq; Albert de la Chapelle; Sissy M Jhiang
Journal:  Thyroid       Date:  2019-02-13       Impact factor: 6.568

6.  Racial and geographic disparities in stage-specific incidence and mortality in the colorectal cancer hotspot region of eastern North Carolina, 2008-2016.

Authors:  Tyler Hinshaw; Suzanne Lea; Justin Arcury; Alexander A Parikh; Rebecca A Snyder
Journal:  Cancer Causes Control       Date:  2021-01-04       Impact factor: 2.506

7.  Haploinsufficiency of SIRT1 Enhances Glutamine Metabolism and Promotes Cancer Development.

Authors:  Natalie S X Ren; Ming Ji; Erik J Tokar; Evan L Busch; Xiaojiang Xu; DeAsia Lewis; Xiangchun Li; Aiwen Jin; Yanping Zhang; William K K Wu; Weichun Huang; Leping Li; David C Fargo; Temitope O Keku; Robert S Sandler; Xiaoling Li
Journal:  Curr Biol       Date:  2017-02-02       Impact factor: 10.834

8.  Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.

Authors:  Krishnansu S Tewari; Michael W Sill; Bradley J Monk; Richard T Penson; Harry J Long; Andrés Poveda; Lisa M Landrum; Mario M Leitao; Jubilee Brown; Thomas J A Reid; Helen E Michael; David H Moore
Journal:  Clin Cancer Res       Date:  2015-12-15       Impact factor: 12.531

9.  Evaluating markers of epithelial-mesenchymal transition to identify cancer patients at risk for metastatic disease.

Authors:  Evan L Busch; Temitope O Keku; David B Richardson; Stephanie M Cohen; David A Eberhard; Christy L Avery; Robert S Sandler
Journal:  Clin Exp Metastasis       Date:  2015-10-27       Impact factor: 5.150

10.  Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Authors:  Frank A Sinicrope; Qian Shi; Thomas C Smyrk; Stephen N Thibodeau; Rodrigo Dienstmann; Justin Guinney; Brian M Bot; Sabine Tejpar; Mauro Delorenzi; Richard M Goldberg; Michelle Mahoney; Daniel J Sargent; Steven R Alberts
Journal:  Gastroenterology       Date:  2014-10-08       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.